PainReform CEO Ilan Hadar Discusses Latest Developments Related To PRF-110 To Help Tackle The Opioid Epidemic
PainReform CEO Ilan Hadar Discusses Latest Developments Related To PRF-110 To Help Tackle The Opioid Epidemic
PainReform Ltd. (NASDAQ:PRFX) ("PainReform" or the "Company"), a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today announced that Ilan Hadar, Chief Executive Officer of PainReform, participated in an interview with Proactiveinvestors.com.
專注於成熟療法配方的臨床階段專業製藥公司PainReform Ltd.（納斯達克股票代碼：PRFX）（“PainReform” 或 “公司”）今天宣佈，PainReform首席執行官伊蘭·哈達爾接受了ProactiveInvestors.com的採訪。
During the interview, Mr. Hadar discussed the advantages of PRF-110 to help tackle the opioid epidemic, including its ability to provide extended post-operative pain relief without the use of opioids, as well as the market potential for the product, and positive updates on the Company's ongoing Phase 3 clinical trial.
在採訪中，哈達爾先生討論了 PRF-110 在幫助應對阿片類藥物流行方面的優勢，包括其在不使用阿片類藥物的情況下延長術後疼痛緩解的能力，以及該產品的市場潛力，以及該公司正在進行的三期臨床試驗的積極進展。
The interview can be viewed on Proactiveinvestors.com or on their YouTube channel:
採訪可以在ProactiveInvestors.com或他們的YouTube頻道上觀看：